Last updated on July 2018

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old With Hodgkin's Lymphoma (cHL) Relapsed or Refractory From First Line Treatment


Brief description of study

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.

Clinical Study Identifier: NCT02927769

Contact Investigators or Research Sites near you

Start Over

Joel Kaplan, Site 0053

Carolinas Medical Center
Charlotte, NC United States
2.89miles
  Connect »